Immune stimulating complexes as mucosal vaccines

Immunology and Cell Biology

Volumn 76, Issue 3, 1998, Pages 263-269

  Smith, Rosemary E ^a   Donachie, Anne M ^a   Mowat, Allan McI ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adjuvant; ISCOMs; Mucosa; Protein antigen; Saponin

Indexed keywords

ISCOM; OVALBUMIN; QUIL A; VACCINE;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; MUCOSA; NONHUMAN;

ANIMALS; HUMANS; IMMUNITY, MUCOSAL; ISCOMS; VACCINATION;

EID: 0031817639     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00749.x     Document Type: Article

References (63)

1. Husband AJ. Novel vaccination strategies for the control of mucosal infection. Vaccine 1993; 11: 107-12.
2. Bloom BR. Vaccines for the Third World. Nature 1989; 342: 115.
3. Challcombe SJ. The induction of secretory IgA responses. In: Food allergy and intolerance. 1987; 269-85.
4. Mowat AMcI. The regulation of immune responses to dietary protein antigens. Immunol. Today 1987; 8: 93-5.
5. Gupta RK, Siber GR. Adjuvants for human vaccines: Current status, problems and future prospects. Vaccine 1995; 13: 1263-76.
6. Lovegren K, Morein B. The requirement of lipids for the formation of immune stimulating complexes (ISCOMs). Biotechnol. Appl. Biochem. 1988; 10: 161-72.
7. Morein B. The ISCOMs antigen-presenting system. Nature 1988; 332; 287-8.
8. Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308: 457-60.
9. Sundquist B, Lövgren K, Morein B. Influenza virus ISCOMs: Antibody response in animals. Vaccine 1988; 6: 49-53.
10. Varsanyi TM, Morein B, Löve A, Norrby E. Protection against lethal measles-virus infection in mice by immuno-stimulating complexes containing the haemagglutinin or fusion protein. J. Virol. 1987; 61: 3896-901.
11. Osterhaus A, Weijer K, UytdeHaag F, Jarrett O, Sundquist B, Morein B. Induction of protective immune response in cats by vaccination with feline leukaemia virus iscom. J. Immunol. 1985; 135: 591-6.
12. Kersten GFA, Teerlink T, Derks HJGK et al. Incorporation of the major outer membrane protein of Neisseria gonorrhoea in saponin-lipid complexes (ISCOMs): Chemical analysis, some structural features and comparison of their immunogenicity with three other antigen delivery systems. Infect. Immun. 1988; 56: 432-8.
13. Morein B, Ekstrom J, Lövgren K. Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms. J. Immunol. Methods 1990; 128: 177-81.
14. Mowat AMcI, Reid G. Preparation of immune stimulating complexes (ISCOMs) as adjuvants. In: Coligan JE, Kruisbeak M, Margulies DH, Shervach EM, Strober W (eds) Current Protocols in Immunology. 1992; 1: 2.11.1-2.11.12. Wiley Interscience.
15. Reid G. Soluble-proteins incorporate into ISCOMs after covalent attachment of fatty acid. Vaccine 1992; 10: 597-602.
16. Browning M, Reid G, Osborne R, Jarrett O. Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralising antibodies. Vaccine 1992; 10: 585-90.
17. Estrada A, Laarveld B, Li B, Redmond MJ. Induction of systemic and mucosal immune responses following immunisation with somatostatin-avidin complexes incorporated into ISCOMs. Imm. Invest. 1995; 24: 819-28.
18. Ertürk M, Jennings R, Hockley D, Potter CW. Antibody responses and protection in mice immunised with herpes simplex virus type I antigen immune-stimulating complex preparations. J. Gen. Virol. 1989; 70: 2149-55.
19. Lövgren K, Kaberg H, Morein B. Influenza virus ISCOMs: antibody response in animals. Vaccine 1988; 82: 435-9.
20. Kersten GFA, van de Put A-M, Teerlink T, Beuvery EC, Crommelin DJA. Immunogenicity of liposomes and ISCOMs containing the major outer membrane protein of Neisseria gonorrhoea: Influence of protein content and liposomal bilayer composition. Infect. Immun. 1988; 56: 1661-4.
21. Nagy B, Hoglund S, Morein B. ISCOMs (immunostimulating complex) vaccines containing mono-r polyvalent pili of enterotoxogenic E. coli; immune response of rabbit and swine. J. Vet. Med. 1990; B37: 728-38.
22. Lövgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunisation with influenza virus immunostimulating complexes. Scand. J. Immunol. 1988; 27: 241-5.
23. Mowat AMcI, Donachic AM, Reid G, Jarrett O. Immune stimulating complexes containing Quil A and protein antigen prime class 1 MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991; 72: 317-22.
24. Fossum C, Bergstrom M, Lövgren K, Watson DL, Morein B. Effect of ISCOMs and their adjuvant moiety (Matrix) on the initial proliferation and IL-2 responses: Comparison of spleen cells from mice inoculated with ISCOMs and/or matrix. Cell. Immunol. 1990; 129: 414-25.
25. Villacrës-Eriksson M, Käberg H, Lövgren K, Morein B. Involvement of interleukin-2 and interferon-gamma in the immune response induced by influenza virus ISCOMs. Scand. J. Immunol. 1992; 36: 421-6.
26. + T cell responses by oral or parenteral immunisation with ISCOMs. Eur. J. Immunol. 1995; 25: 2835-41.
27. Villacrës-Eriksson M. Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes. Clin. Exp. Immunol. 1995; 102: 46-52.
28. Sjölander A, van't Land B, Lövgren-Bengtsson K. ISCOMs containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell. Immunol. 1997; 177: 69-76.
29. Morein B, Lövgren K, Höglund S, Sundquist B. The ISCOMs: An immunostimulating complex. Immunol. Today 1987; 8: 333-8.
30. Morein B, Lövgren K, Rönnberg B, Sjölander A, Villacrës-Eriksson M. Immunostimulating complexes. Clin. Immunother. 1995; 3: 461-75.
31. Kersten GFA, Crommelin DJA. Liposomes and ISCOMs as vaccine formulations. Biochim. Biophys. Acta 1995; 1241: 117-38.
32. Takahashi H, Takeshita T, Morein B. Induction of CD8+ cytotoxic T cells by immunisation with purified HIV-envelope proteins in iscoms. Nature 1990; 344: 873-5.
33. + cytotoxic T lymphocytes towards soluble antigens: Immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitisation against the immunodominant peptide. J. Immunol. 1991; 21: 1523-7.
34. Jones PD, Tha Hla R, Morein B, Lövgren K, Ada GL. Cellular immune responses in the murine lung to local immunisation with influenza A virus glycoproteins in micelles and immunostimulatory complexes (ISCOMs). Scand. J. Immunol. 1988; 27: 645-52.
35. Trudel M, Nadon F, Sëguin C, Brault S, Lusignan Y. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine 1992; 10: 107-12.
36. Mowat AMcI, Maloy KJ, Donachie AM. Immune stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunisation with protein antigens. Immunology 1993; 80: 527-34.
37. Campbell JB, Peerbaye YA. Saponin. Res. Immunol. 1992; 143: 526-30.
38. Maloy KJ. The basis of the oral and parenteral adjuvant properties of immune stimulating complexes (ISCOMs). PhD thesis. University of Glasgow, Glasgow, UK. 1996.
39. Debrick JE, Campbell PA, Staerz UD. Macrophages as accessory for class I MHC-restricted immune responses. J. Immunol. 1991; 147: 2846-51.
40. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA 1993; 90: 4942-6.
41. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 1994; 153: 4925-33.
42. Lövgren K, Kaberg H, Morein B. An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. J. Exp. Immunol. 1990; 82: 435-9.
43. Charles SD, Hussain I, Choi CU, Nagaraja KV, Sivanandan V. Adjuvented subunit vaccines for the control of Salmonella enteritidis infection in turkeys. Am. J. Vet. Res. 1994; 55: 636-42.
44. Araujo FG, Morein B. Immunisation with Trypanosoma cruzi epimastigote antigens incorporated into ISCOMs protects against lethal challenge in mice. Infect. Immun. 1991; 59: 2909-14.
45. Overness G, Nesse NN, Waldeland N, Lövgren K, Gudding R. Immune response after immunisation with an experimental Toxoplasma gondii ISCOMs. Vaccine 1991; 9: 25-8.
46. Hsu S-C, Schadeck EB, Delmas A, Shaw M, Steward MW. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and the induction of CTL responses following intranasal immunisation. Vaccine 1996; 14: 1159-66.
47. Kersten GFA. Aspects of ISCOMs. Analytical, pharmaceutical and adjuvant properties. PhD thesis, University of Utrecht, Utrecht, Holland. 1990.
48. Chavali SR, Campbell J. Immunomodulatory effects of orally-administered saponins and non-specific resistance against rabies infection. Int. Arch. Allergy Appl. Immun. 1987; 84: 129-34.
49. Chavali SR, Campbell J. Adjuvant effects of orally administered saponins on humoral and cell-mediated immune responses in mice. Immunobiology 1987; 174: 347-59.
50. Ghazi HO, Potter CW, Smith TL, Jennings R. Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs. Viral Vaccines 1995; 42: 53-61.
51. Scheepers K, Becht H. Protection of mice against an influenza-virus infection by oral vaccination with viral nucleoprotein incorporated into immunostimulating complexes. Med. Microbiol. Immunol. 1994; 183: 265-78.
52. Kazanji M, Laurent F, Perry P. Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMs. Vaccine 1994; 12: 798-804.
53. Phillips JC, Butterworth KR, Gaunt IF, Evans JG, Grasso P. Long-term toxicity study of Quillaja extract in mice. Food Cosmet. Toxicol. 1979; 17: 23-7.
54. Thapar MA, Parr EJ, Bozzola JJ, Parr MB. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunisation with an immunostimulating complex (ISCOMs). Vaccine 1991; 9: 129-33.
55. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AMcI. Induction of mucosal and systemic immune responses by immunisation with ovalbumin entrapped in poly (lactide-coglycolide) microparticles. Immunology 1994; 81: 661-7.
56. Claassen I, Osterhaus A, Boersma WJA, Chellekens MM, Claassen E. Fluorescent labelling of virus, bacteria and ISCOMs: In vivo systemic and mucosal localisation patterns. In: Brandtzaeg P, McGhee JR, Mestecky J, Sterzl G, Tlaskalova H (eds) Advances in Mucosal Immunology. New York: Plenum Press, 1992.
57. Villacres-Eriksson M. Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes. Clin. Exp. Immunol. 1995; 102: 46-52.
58. Behboudi S, Morein B, Villacres-Eriksson M. In vivo and in vitro induction of IL-6 by Quillaja saponaria Molina triterpenoid formulations. Cytokine 1997; 9: 682-7.
59. Villacres-Eriksson M, Behboudi S, Morgan AJ, Trinchieri G, Morein B. Immunomodulation by Quillaja saponaria adjuvant formulations: In vivo stimulation of interleukin 12 and its effects on the antibody response. Cytokine 1997; 9: 73.
60. Smith RE, Donachie AM, McLaren FH, Mowat AMcI. Preservation of systemic and mucosal immune responses to immune stimulating complexes in the absence of functional interleukin 4 or γ interferon. Immunology 1998; 93: 556-62.
61. Kato T, Yamane H, Nariuchi H. Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages. Cell. Immunol. 1997; 181: 59-67.
62. Vajdy M, Kosco-Vilbois, Kopf M, Köhler G, Lycke N. Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 1995; 181: 41-53.
63. Rönnberg B, Makonnen F, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOMs matrix. Vaccine 1995; 13: 1375-82.